Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2059PDF: 1653HTML: 360 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2425PDF: 779HTML: 1729 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1343HTML: 382PDF: 810 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2113PDF: 1316HTML: 3494 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1929PDF: 735HTML: 686 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2777PDF: 1000HTML: 5509 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2129PDF: 1452HTML: 258 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2499PDF: 864HTML: 2113 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
1982PDF: 751HTML: 3106 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
2889PDF: 871HTML: 1571 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2168PDF: 791HTML: 1619Figure 1: 176Table 1: 197 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2548PDF: 731HTML: 2290 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1208PDF: 968HTML: 197 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4267PDF: 1743HTML: 1100 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2871PDF: 1575HTML: 224 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3557PDF: 870HTML: 6702 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7382PDF: 2403HTML: 1715Table 1.: 201Table 2.: 213Table 3.: 194Table 4.: 194 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3207PDF: 928HTML: 2937 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1293PDF: 799HTML: 122 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2800PDF: 843HTML: 6509Untitled: 221Untitled: 182Untitled: 195Untitled: 204 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1752PDF: 960HTML: 134 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1803PDF: 707HTML: 2094Untitled: 205Untitled: 149Untitled: 166Untitled: 150Untitled: 158Untitled: 173Untitled: 181 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1545PDF: 495HTML: 153 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1360PDF: 1294HTML: 89 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1439PDF: 756HTML: 196 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3831PDF: 745HTML: 1836 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1576PDF: 797HTML: 154 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1744PDF: 560HTML: 271
1 - 47 of 47 items







